Navigation Links
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Date:7/10/2012

LONDON, July 11, 2012 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1. The study demonstrated superiority of the dolutegravir-based regimen compared to the single tablet regimen Atripla®.  At 48 weeks, 88% of study participants on the dolutegravir regimen were virologically suppressed (<50 copies/mL) vs. 81% of participants on the single tablet regimen Atripla [difference and 95% CI; 7.4% (+2.5% to +12.3%); difference in the primary endpoint was statistically significant, p=0.003]. Differences in efficacy were primarily driven by a higher rate of discontinuation due to adverse events on the Atripla arm. The SINGLE study was designed to demonstrate non-inferiority of the dolutegravir-based regimen versus Atripla, and the primary analysis met this criterion.  Statistical superiority was concluded as part of a subsequent, pre-specified testing procedure.

SINGLE is an ongoing double blind, double dummy study designed to compare the efficacy and safety of two antiretroviral regimens: dolutegravir 50mg plus abacavir/lamivudine (Kivexa®/Epzicom®) versus Atripla® (tenofovir/emtricitabine/efavirenz). The primary endpoint was the proportion of study participants with undetectable HIV-1 RNA (<50c/mL) at 48 weeks; 414 treatment-naive study participants were randomised and exposed to the dolutegravir-based  regimen and 419 to the Atripla arm.  Overall, 2% of subjects on the dolutegravir-based regimen discontinued due to adverse events vs. 10% of those receiving the Atripla regimen. The most common drug related adverse events on Atripla were in the nervous system System Organ Class (reported by 41% of Atripla recipients, vs. 15% of participants receiving the dolutegravir-based regimen), while the most common drug relat
'/>"/>

SOURCE Shionogi-ViiV Healthcare LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Netsmarts Focus on Innovation to Help Health and Human Service Providers Span the Spectrum of Care in the Healthcare 3.0 Environment
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
7. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
8. Med Ad News Honors Healthcare Communication Agencies at 23rd Annual Manny Awards
9. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
10. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
11. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015   Cochlear Limited ... hearing solutions, announced today the US Food and ... Profile™ Implant with Slim Straight Electrode (CI522). Built ... in close collaboration with the world,s leading surgeons, ... platform designed to provide the most discreet appearance ...
(Date:7/1/2015)... DUBLIN , June 24, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/34xqr7/2015_new ) has announced the addition of ... Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, ... their offering. 2015 New Frontiers ... Business Challenges, Emerging Technologies, Competitive Landscape is ...
(Date:7/1/2015)... July 1, 2015  goBalto, Inc., the leading ... today unprecedented growth in serving pharmaceutical, biotech and ... to speed clinical trials and restrain costs, but ... methods have stalled these efforts," said Sujay ... clinical trials has encouraged Industry leaders, to embrace ...
Breaking Medicine Technology:Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 32015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 2goBalto Triples Sites Managed, Further Reinforcing Market Leadership Position 2
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Sir Fazle ... annual World Food Prize today. Sir Fazle has been recognised for his outstanding contribution ... , Ambassador Ken Quinn, President of the World Food Prize Foundation, announced this ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... announced that they will welcome four new members to their industry leading Scientific ...
(Date:7/1/2015)... ... July 01, 2015 , ... DIC Corporation today announced the ... natural blue food coloring. Construction of the plant, which is located on the ... began in May 2014. After commissioning, commercial production is expected to begin in ...
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® ... Hospital Corporation of America (HCA), as it further expands its Strategic Alliance Partnership ... , With this new partnership, OncLive’s editorial and marketing teams will collaborate with ...
(Date:7/1/2015)... ... ... The 28th annual Charity Horse Show hosted by the Mid-South Horse Show Association ... Pugh Bourne Park, 343 Oakfield Road. The event will again benefit Youth Town. , ... silent auction and concessions. , Horses and riders from around the country will participate ...
Breaking Medicine News(10 mins):Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3
... the battle against malignant brain tumors, dual implantation ... showed promising results in a study led by ... of Cincinnati (UC) and University Hospital. , The ... Journal of Neurosurgery, revealed that patients treated with ...
... Gornick LLP, Bailey Perrin Bailey LLP and Weitz &, ... United, States District Court for the Eastern District of New York ... Co., Inc. and Schering-Plough Corporation., ... the law,firms of Parker Waichman Alonso LLP, Becnel Law Firm, LLC, ...
... Five Such Cases Known Worldwide, NEW HYDE PARK, N.Y., ... physicians at LIJ Medical,Center, 25-year-old Stacey Gayle can now look ... radio. At a news conference today, Ms.,Gayle and her doctors ... robbed her of her health, but of the very important,gift ...
... Jan Marini Skin Research,Inc. (JMSR; http://www.janmarini.com ) today ... Age Intervention Eyelash Conditioner,and Age Intervention Masses of Lashes ... patent infringement lawsuit by Allergan Pharmaceutical as,one reason for ... suspend,these products while we strategically review our options," said ...
... general use, experts caution , , THURSDAY, Jan. 17 (HealthDay News)-- Some ... modifies the body,s immune response. , A study in the Jan. ... no history of heart attacks, as well as those in a ... and of subsequent hospitalizations with such a treatment. , But ...
... a lack of knowledge of health risks posed by ... cell phone technology and use continues to expand and evolve, ... potential health risks associated with long-term exposure to radiofrequency energy. ... women and fetuses -- as well as workers subject to ...
Cached Medicine News:Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2Health News:Former Sufferer of Rare Disease Called Musicogenic Epilepsy Thanks LIJ Medical Team That Ended Her Seizures and Gave Her Back the Gift of Music 2Health News:Jan Marini Skin Research Suspends Sales of Popular Eyelash Products 2Health News:Immune Therapy May Help Some Heart Failure Patients 2Health News:Immune Therapy May Help Some Heart Failure Patients 3Health News:Report Urges More Research Into Cell Phones 2Health News:Report Urges More Research Into Cell Phones 3
... The Auto Suture™ VERSAPORT™ PLUS RPF trocar ... mm long, 5 mm-11 mm, 5 mm-12 mm, ... sleeve and shield. , ,The VERSAPORT™ PLUS ... a spring-loaded shield. Upon entry into a free ...
The SURGINEEDLE™ is a veress type needle that is used to insufflate the abdomen to create pneumoperitoneum....
... The complete line of Surgical Access ...unlike ... ,The OnePort™ trocar system is actually four ... versatile, operationally flexible and clinically adaptive to ... options in disposability and bladed or dilating ...
... The complete line of Surgical Access ...unlike ... ,The OnePort™ trocar system is actually four ... versatile, operationally flexible and clinically adaptive to ... options in disposability and bladed or dilating ...
Medicine Products: